Novel SA53 MDM2 Inhibitor Therapy Has Potential to be a Breakthrough in Genetically-Targeted Cancer Treatment (CLEVELAND, OH) – Lamassu Biotech, a clinical-stage pharmaceutical company, today announced a significant clinical milestone...
Tag: SA53